DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer.

IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY
Stefanie Korsgaard Körner, Thomas Dreyer, Andreas Carus, Line Hammer Dohn, Ulla Nordström Joensen, Gitte Wrist Lam, Niels Viggo Jensen, Knud Fabrin, Thor Knak Jensen, Helle Pappot, Mads Agerbæk, Jørgen Bjerggaard Jensen
{"title":"DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer.","authors":"Stefanie Korsgaard Körner, Thomas Dreyer, Andreas Carus, Line Hammer Dohn, Ulla Nordström Joensen, Gitte Wrist Lam, Niels Viggo Jensen, Knud Fabrin, Thor Knak Jensen, Helle Pappot, Mads Agerbæk, Jørgen Bjerggaard Jensen","doi":"10.2340/sju.v59.24024","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the impact of neoadjuvant chemotherapy implementation with gemcitabine-cisplatin on survival outcomes for patients with muscle-invasive bladder cancer in Denmark.</p><p><strong>Materials and methods: </strong>Data were collected on all patients in Denmark undergoing radical cystectomy who were potential candidates for neoadjuvant chemotherapy from 2010 to 2015 (n = 851). A cohort before the implementation of neoadjuvant chemotherapy (Cohort 2010-12) was compared with a cohort after implementation (Cohort 2013-15). Patients in Cohort 2013-15 receiving neoadjuvant chemotherapy (+NAC, n = 213) were compared with patients in Cohort 2013-15 not receiving neoadjuvant chemotherapy (-NAC, n = 139). Pathological results after radical cystectomy and oncological outcomes were compared between the study cohorts. Overall survival, disease-free survival, and disease-specific survival were compared with Kaplan-Meier plots and with univariable and multivariable Cox regression. Kaplan-Meier estimates of overall survival were also performed separately for treating hospital and for pathological stage.</p><p><strong>Results: </strong>Pathological T0 (pT0) was more frequent in patients who received neoadjuvant chemotherapy: 34% versus 18% when comparing Cohort 2013-15 with Cohort 2010-12 (p < 0.001), and 46% versus 16% in +NAC compared with -NAC (p < 0.001). Overall survival, disease-free survival, and disease-specific survival at 5 years after cystectomy were not improved in Cohort 2013-15 compared with Cohort 2010-12 with adjusted hazard ratios of 1.11 (95% confidence interval [CI]: 0.87-1.43), 1.02 (95% CI: 0.81-1.29), and 1.06 (95% CI: 0.80-1.41), respectively.</p><p><strong>Conclusions: </strong>This observational study found no improved survival in a national cohort of patients with muscle-invasive bladder cancer undergoing radical cystectomy after implementation of NAC. However, reservations should be made regarding the study design and the true effect of NAC on survival outcomes.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"59 ","pages":"39-46"},"PeriodicalIF":1.4000,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/sju.v59.24024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To investigate the impact of neoadjuvant chemotherapy implementation with gemcitabine-cisplatin on survival outcomes for patients with muscle-invasive bladder cancer in Denmark.

Materials and methods: Data were collected on all patients in Denmark undergoing radical cystectomy who were potential candidates for neoadjuvant chemotherapy from 2010 to 2015 (n = 851). A cohort before the implementation of neoadjuvant chemotherapy (Cohort 2010-12) was compared with a cohort after implementation (Cohort 2013-15). Patients in Cohort 2013-15 receiving neoadjuvant chemotherapy (+NAC, n = 213) were compared with patients in Cohort 2013-15 not receiving neoadjuvant chemotherapy (-NAC, n = 139). Pathological results after radical cystectomy and oncological outcomes were compared between the study cohorts. Overall survival, disease-free survival, and disease-specific survival were compared with Kaplan-Meier plots and with univariable and multivariable Cox regression. Kaplan-Meier estimates of overall survival were also performed separately for treating hospital and for pathological stage.

Results: Pathological T0 (pT0) was more frequent in patients who received neoadjuvant chemotherapy: 34% versus 18% when comparing Cohort 2013-15 with Cohort 2010-12 (p < 0.001), and 46% versus 16% in +NAC compared with -NAC (p < 0.001). Overall survival, disease-free survival, and disease-specific survival at 5 years after cystectomy were not improved in Cohort 2013-15 compared with Cohort 2010-12 with adjusted hazard ratios of 1.11 (95% confidence interval [CI]: 0.87-1.43), 1.02 (95% CI: 0.81-1.29), and 1.06 (95% CI: 0.80-1.41), respectively.

Conclusions: This observational study found no improved survival in a national cohort of patients with muscle-invasive bladder cancer undergoing radical cystectomy after implementation of NAC. However, reservations should be made regarding the study design and the true effect of NAC on survival outcomes.

DaBlaCa-17:在丹麦开展的全国性观察研究,研究肌肉浸润性膀胱癌膀胱切除术前实施新辅助化疗前后的生存情况。
摘要研究丹麦肌肉浸润性膀胱癌患者实施吉西他滨-顺铂新辅助化疗对生存结果的影响:收集了2010年至2015年期间丹麦所有接受根治性膀胱切除术的潜在新辅助化疗候选患者的数据(n = 851)。新辅助化疗实施前的队列(2010-12年队列)与实施后的队列(2013-15年队列)进行了比较。2013-15年队列中接受新辅助化疗的患者(+NAC,n = 213)与2013-15年队列中未接受新辅助化疗的患者(-NAC,n = 139)进行了比较。比较了两组患者根治性膀胱切除术后的病理结果和肿瘤治疗效果。通过卡普兰-梅耶图以及单变量和多变量考克斯回归比较了总生存率、无病生存率和疾病特异性生存率。此外,还根据治疗医院和病理分期分别对总生存期进行了卡普兰-梅耶估计:接受新辅助化疗的患者病理分期为T0(pT0)的比例更高:2013-15队列与2010-12队列相比,前者为34%,后者为18%(P < 0.001);+NAC与-NAC相比,前者为46%,后者为16%(P < 0.001)。与2010-12队列相比,2013-15队列的总生存率、无病生存率和膀胱切除术后5年的疾病特异性生存率均未得到改善,调整后的危险比分别为1.11(95% 置信区间[CI]:0.87-1.43)、1.02(95% CI:0.81-1.29)和1.06(95% CI:0.80-1.41):这项观察性研究发现,在全国接受根治性膀胱切除术的肌层浸润性膀胱癌患者队列中,实施 NAC 后患者的生存率没有提高。然而,对于研究设计和 NAC 对生存结果的真正影响,我们还需持保留意见。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Scandinavian Journal of Urology
Scandinavian Journal of Urology UROLOGY & NEPHROLOGY-
CiteScore
2.90
自引率
6.70%
发文量
70
期刊介绍: Scandinavian Journal of Urology is a journal for the clinical urologist and publishes papers within all fields in clinical urology. Experimental papers related to clinical questions are also invited.Important reports with great news value are published promptly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信